{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:17:41Z","timestamp":1788617861022,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T00:00:00Z","timestamp":1662508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03183-9","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T08:03:54Z","timestamp":1662537834000},"page":"543-551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic significance of lung metastasis-related finding in lenvatinib treatment for differentiated thyroid cancer"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6640-3529","authenticated-orcid":false,"given":"Haruhiko","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Masudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soji","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Rino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,7]]},"reference":[{"key":"3183_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021)","journal-title":"CA Cancer J. Clin."},{"key":"3183_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1089\/thy.2021.0662","volume":"32","author":"U Megwalu","year":"2022","unstructured":"U. Megwalu, P.K. Moon, Thyroid cancer incidence and mortality trends in the United States: 2000\u20132018. Thyroid 32, 560\u2013570 (2022)","journal-title":"Thyroid"},{"key":"3183_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ctrv.2015.11.003","volume":"42","author":"ME Cabanillas","year":"2016","unstructured":"M.E. Cabanillas, M.A. Habra, Lenvatinib: role in thyroid cancer and other solid tumors. Cancer Treat. Rev. 42, 47\u201355 (2016)","journal-title":"Cancer Treat. Rev."},{"key":"3183_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1\u2013133 (2016)","journal-title":"Thyroid"},{"key":"3183_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621\u2013630 (2015)","journal-title":"N. Engl. J. Med."},{"key":"3183_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2020.12.032","volume":"147","author":"M Tahara","year":"2021","unstructured":"M. Tahara, N. Kiyota, A.O. Hoff, C. Badiu, T.K. Owonikoko, C.E. Dutcus, T. Suzuki, M. Ren, L.J. Wirth, Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer. Eur. J. Cancer 147, 51\u201357 (2021)","journal-title":"Eur. J. Cancer"},{"key":"3183_CR7","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/cncr.34181","volume":"128","author":"N Kiyota","year":"2022","unstructured":"N. Kiyota, M. Tahara, B. Robinson, M. Schlumberger, S.I. Sherman, S. Leboulleux, E.K. Lee, T. Suzuki, M. Ren, K. Fushimi, L.J. Wirth, Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial. Cancer 128, 2281\u20132287 (2022)","journal-title":"Cancer"},{"key":"3183_CR8","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1089\/thy.2020.0779","volume":"31","author":"MH Taylor","year":"2021","unstructured":"M.H. Taylor, S. Takahashi, J. Capdevila, M. Tahara, S. Leboulleux, N. Kiyota, C.E. Dutcus, R. Xie, B. Robinson, S. Sherman, M.A. Habra, R. Elisei, L.J. Wirth, Correlation of performance status and neutrophil-lymphocyte ratio with efficacy in radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. Thyroid 31, 1226\u20131234 (2021)","journal-title":"Thyroid"},{"key":"3183_CR9","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/cas.12826","volume":"106","author":"N Kiyota","year":"2015","unstructured":"N. Kiyota, M. Schlumberger, K. Muro, Y. Ando, S. Takahashi, Y. Kawai, L. Wirth, B. Robinson, S. Sherman, T. Suzuki, K. Fujino, A. Gupta, S. Hayato, M. Tahara, Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 106, 1714\u20131721 (2015)","journal-title":"Cancer Sci."},{"key":"3183_CR10","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1097\/IJ9.0000000000000104","volume":"5","author":"H Iwasaki","year":"2020","unstructured":"H. Iwasaki, S. Toda, D. Murayama, A. Matsui, Analysis of disease progression and prognosis in differentiated thyroid cancer with pulmonary metastases: a retrospective study. Int. J. Surg. Oncol. 5, e104 (2020)","journal-title":"Int. J. Surg. Oncol."},{"key":"3183_CR11","doi-asserted-by":"publisher","first-page":"e14774","DOI":"10.1097\/MD.0000000000014774","volume":"98","author":"H Yamazaki","year":"2019","unstructured":"H. Yamazaki, H. Iwasaki, H. Takasaki, N. Suganuma, R. Sakai, K. Masudo, H. Nakayama, Y. Rino, M. Masuda, Efficacy and tolerability of initial low-dose lenvatinib to treat differentiated thyroid cancer. Medicine 98, e14774 (2019)","journal-title":"Medicine"},{"key":"3183_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009)","journal-title":"Eur. J. Cancer"},{"key":"3183_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Y. Kanda, Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48, 452\u2013458 (2013)","journal-title":"Bone Marrow Transpl."},{"key":"3183_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1530\/ERC-18-0049","volume":"25","author":"AG Gianoukakis","year":"2018","unstructured":"A.G. Gianoukakis, C.E. Dutcus, N. Batty, M. Guo, M. Baig, Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr. Relat. Cancer 25, 699\u2013704 (2018)","journal-title":"Endocr. Relat. Cancer"},{"key":"3183_CR15","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO.2016.71.6472","volume":"35","author":"MS Brose","year":"2017","unstructured":"M.S. Brose, F.P. Worden, K.L. Newbold, M. Guo, A. Hurria, Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J. Clin. Oncol. 35, 2692\u20132699 (2017)","journal-title":"J. Clin. Oncol."},{"key":"3183_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1089\/thy.2018.0582","volume":"29","author":"D Wu","year":"2019","unstructured":"D. Wu, C.J. Gomes Lima, S.L. Moreau, K. Kulkarni, A. Zeymo, K.D. Burman, L. Wartofsky, D. Van Nostrand, Improved survival after multimodal approach with 131 I treatment in patients with bone metastases secondary to differentiated thyroid cancer. Thyroid 29, 971\u2013978 (2019)","journal-title":"Thyroid"},{"key":"3183_CR17","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1007\/s00268-018-4676-9","volume":"42","author":"Y Saito","year":"2018","unstructured":"Y. Saito, K. Sugino, H. Takami, K. Matsuzu, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, H. Kawakubo, K. Ito, Y. Kitagawa, Clinical status and treatment of liver metastasis of differentiated thyroid cancer using tyrosine kinase inhibitors. World J. Surg. 42, 3632\u20133637 (2018)","journal-title":"World J. Surg."},{"key":"3183_CR18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1007\/s00268-016-3405-5","volume":"40","author":"F Saito","year":"2016","unstructured":"F. Saito, T. Uruno, H. Shibuya, W. Kitagawa, M. Nagahama, K. Sugino, K. Ito, Prognosis after brain metastasis from differentiated thyroid carcinoma. World J. Surg. 40, 574\u2013581 (2016)","journal-title":"World J. Surg."},{"key":"3183_CR19","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1530\/EC-20-0193","volume":"9","author":"DT Broome","year":"2020","unstructured":"D.T. Broome, G.B. Gadre, E. Fayazzadeh, J.F. Bena, C. Nasr, Pleural effusion as a novel prognostic factor in metastatic thyroid carcinoma. Endocr. Connect 9, 812\u2013823 (2020)","journal-title":"Endocr. Connect"},{"key":"3183_CR20","doi-asserted-by":"publisher","first-page":"e19408","DOI":"10.1097\/MD.0000000000019408","volume":"99","author":"H Yamazaki","year":"2020","unstructured":"H. Yamazaki, K. Sugino, K. Matsuzu, C. Masaki, J. Akaishi, K. Hames, C. Tomoda, A. Suzuki, T. Uruno, K. Ohkuwa, W. Kitagawa, M. Nagahama, M. Masuda, K. Ito, Rapid disease progression after discontinuation of lenvatinib in thyroid cancer. Medicine 99, e19408 (2020)","journal-title":"Medicine"},{"key":"3183_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1507\/endocrj.EJ17-0365","volume":"65","author":"K Sugino","year":"2018","unstructured":"K. Sugino, M. Nagahama, W. Kitagawa, K. Ohkuwa, T. Uruno, K. Matsuzu, A. Suzuki, C. Masaki, J. Akaishi, K.Y. Hames, C. Tomoda, Y. Ogimi, K. Ito, Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Endocr. J. 65, 299\u2013306 (2018)","journal-title":"Endocr. J."},{"key":"3183_CR22","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1002\/cncr.29395","volume":"121","author":"ME Cabanillas","year":"2015","unstructured":"M.E. Cabanillas, M. Schlumberger, B. Jarzab, R.G. Martins, F. Pacini, B. Robinson, J.C. McCaffrey, M.H. Shah, D.L. Bodenner, D. Topliss, C. Andresen, J.P. O\u2019Brien, M. Ren, Y. Funahashi, R. Allison, R. Elisei, K. Newbold, L.F. Licitra, S.I. Sherman, D.W. Ball, A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment. Cancer 121, 2749\u20132756 (2015)","journal-title":"Cancer"},{"key":"3183_CR23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1210\/clinem\/dgab731","volume":"107","author":"MS Brose","year":"2020","unstructured":"M.S. Brose, Y. Panaseykin, B. Konda, C. de la Fouchardiere, B.G.M. Hughes, A.G. Gianoukakis, Y. Joo Park, I. Romanov, M.K. Krzyzanowska, S. Leboulleux, T.A. Binder, C. Dutcus, R. Xie, M.H. Taylor, A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 107, 776\u2013787 (2020)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3183_CR24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1089\/thy.2019.0476","volume":"30","author":"E Song","year":"2020","unstructured":"E. Song, M. Kim, E.Y. Kim, B.H. Kim, D.Y. Shin, H.C. Kang, B.C. Ahn, W.B. Kim, Y.K. Shong, M.J. Jeon, D.J. Lim, Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea. Thyroid 30, 732\u2013738 (2020)","journal-title":"Thyroid"},{"key":"3183_CR25","doi-asserted-by":"publisher","first-page":"7139","DOI":"10.2147\/CMAR.S326255","volume":"13","author":"HJ Jiang","year":"2021","unstructured":"H.J. Jiang, Y.H. Chang, Y.H. Chen, C.W. Wu, P.W. Wang, P.J. Hsiao, Low dose of lenvatinib treatment for patients of radioiodine-refractory differentiated thyroid carcinoma\u2014a real-world experience. Cancer Manag. Res. 13, 7139\u20137148 (2021)","journal-title":"Cancer Manag. Res."},{"key":"3183_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41820-y","volume":"9","author":"T Ozeki","year":"2019","unstructured":"T. Ozeki, M. Nagahama, K. Fujita, A. Suzuki, K. Sugino, K. Ito, M. Miura, Influence of CYP3A4\/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci. Rep. 9, 5404 (2019)","journal-title":"Sci. Rep."},{"key":"3183_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-019-1263-3","volume":"36","author":"M Nagahama","year":"2019","unstructured":"M. Nagahama, T. Ozeki, A. Suzuki, K. Sugino, T. Niioka, K. Ito, M. Miura, Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer. Med Oncol. 36, 39 (2019)","journal-title":"Med Oncol."},{"key":"3183_CR28","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3390\/cancers12041010","volume":"12","author":"H Iwamoto","year":"2020","unstructured":"H. Iwamoto, H. Suzuki, S. Shimose, T. Niizeki, M. Nakano, T. Shirono, S. Okamura, Y. Noda, N. Kamachi, T. Nakamura, A. Masuda, T. Sakaue, T. Tanaka, D. Nakano, M. Sakai, T. Yamaguchi, R. Kuromatsu, H. Koga, T. Torimura, Weekends-off lenvatinib for unresectable hepatocellular carcinoma improves therapeutic response and tolerability toward adverse events. Cancers 12, 1010 (2020)","journal-title":"Cancers"},{"key":"3183_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ejca.2017.01.013","volume":"75","author":"M Tahara","year":"2017","unstructured":"M. Tahara, M. Schlumberger, R. Elisei, M.A. Habra, N. Kiyota, R. Paschke, C.E. Dutcus, T. Hihara, S. McGrath, M. Matijevic, T. Kadowaki, Y. Funahashi, S.I. Sherman, Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur. J. Cancer 75, 213\u2013221 (2017)","journal-title":"Eur. J. Cancer"},{"key":"3183_CR30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00228-020-02842-y","volume":"76","author":"H Yamazaki","year":"2020","unstructured":"H. Yamazaki, T. Yokose, H. Hayashi, H. Iwasaki, S. Osanai, N. Suganuma, H. Nakayama, K. Masudo, Y. Rino, M. Masuda, Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study. Eur. J. Clin. Pharm. 76, 703\u2013709 (2020)","journal-title":"Eur. J. Clin. Pharm."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03183-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03183-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03183-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T09:32:16Z","timestamp":1667640736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03183-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,7]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3183"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03183-9","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,7]]},"assertion":[{"value":"26 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Review Board of Kanagawa Cancer Center (IRB approval no. 2022-4) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}